Infectious diseases plague mankind; with infections responsible for approximately 20% of all deaths worldwide. New strategies are urgently needed and we have positioned our research to address questions around how to forestall bacterial pathogens in the initial phases of invasion of human tissues and provide full understanding of the key molecules on the surfaces of bacterial cells. This fundamental knowledge is crucial to new drugs, vaccines and infection-resistant medical devices.
Biomarkers To Aid Clinical Trials For Neurodegenerative Disease
Funder
National Health and Medical Research Council
Funding Amount
$13,179,875.00
Summary
Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effective drugs currently available. Whilst these diseases present with different symptoms, we’ve discovered that they share a common underlying feature; the inability to clear certain metals and proteins from the brain. Our program aims to explore these clearance pathways in the brain and identify new targets to help us better diagnose and treat these diseases.
Optimising Heart Disease Prevention And Management
Funder
National Health and Medical Research Council
Funding Amount
$4,647,175.00
Summary
As we become older and risk factors such as obesity become more common, our biggest contributor to death and disability, cardiovascular disease (including heart disease), will continue to exert an enormous burden on our health care system and society. We will extend our ground-breaking research on multidisciplinary teams to create new and innovative health care programs to optimise the prevention and management of new heart disease and chronic forms of heart disease.
Optimisation Of Wolbachia Based Control Strategies To Reduce Dengue Incidence And Disease
Funder
National Health and Medical Research Council
Funding Amount
$6,073,640.00
Summary
The project will build on recent advances in the use of Wolbachia infected mosquitoes to limit dengue transmission. Key outcomes will include improved understanding of Wolbachia spread after release, development of techniques for regional spread, understanding the epidemiology of dengue transmission in Vietnam and preparing a panel of new Wolbachia:A. aegypti strain combinations for evaluation for implementation programs.
Clinical, Public Health And Policy Interventions To Combat Cardiovascular Diseases
Funder
National Health and Medical Research Council
Funding Amount
$24,025,090.00
Summary
This program will generate and translate evidence from high-quality research designed to inform the decisions of health care providers and policy makers about best strategies for the prevention and treatment of cardiometabolic conditions. The program, with both domestic and global relevance, will address a spectrum of issues, with translational outcomes for clinical research.
Dengue, Zika and Chikungunya are viral diseases transmitted to humans by mosquitoes. Our research uses a naturally-occurring bacteria, Wolbachia, to stop mosquitoes transmitting these viruses to humans. Our proposal addresses critical knowledge gaps in the biology of mosquitoes and Wolbachia to enable large-scale field-deployment optimisation in affected countries. The outcome of our research will immediately translate to disease control efforts in northern Australia, Asia and Latin America.
Protein Glycan Interactions In Infectious Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$9,182,220.00
Summary
Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st centu ....Infectious diseases remain a serious threat to human health, accounting for over 10 million deaths each year. This is a broad-based collaborative proposal, building on our previous achievements. Its aim is to better understand the dynamic interactions between major disease-causing microbes and their human hosts, and to directly apply this new knowledge to the development of improved vaccines and novel treatment strategies. These are urgently needed to combat infectious diseases in the 21st century.Read moreRead less
Finding New Evidence Based Therapies For Treating Heart Disease And Stimulating Regeneration
Funder
National Health and Medical Research Council
Funding Amount
$11,088,182.00
Summary
Heart disease is the leading cause of death and disability in our society. This interactive team of clinicians and basic scientists will exploit the latest advances in genome technology and stem cell biology to gain greater insights into the genetic basis of heart disease, elucidate the molecular mechanisms of cardiac function and disease and translate these insights into the development of novel therapeutic approaches for the prevention and treatment of heart disease.
A PROGRAM OF TRANSLATIONAL CARDIOVASCULAR MEDICINE: IDENTIFYING NEW TARGETS FOR PREVENTION AND TREATMENT
Funder
National Health and Medical Research Council
Funding Amount
$13,050,773.00
Summary
Cardiovascular disease (CVD) is the major cause of death and disability in Australia and worldwide, despite signficant advances in treatment. Our team has an international reputation for developing innovative approaches for the treatment of patients with CVD. We will work collaboratively to improve outcomes for people suffering from hypertension, heart attack, heart failure & other serious forms of CVD.
This Program Grant brings together a world-leading team of experts to elucidate mechanisms that protect most people from infection by making antibodies, and their failure caused by genes or infections like influenza or HIV. The team will determine mechanisms that protect most people from making antibodies against normal parts of our body, whose failure causes numerous autoimmune diseases including rheumatoid arthritis. The team will develop ways to engineer better antibodies.